Tim Demuth, MD, PhD
Executive Medical Advisor
Tim Demuth, MD, PhD, Executive Medical Advisor at Worldwide Clinical Trials, brings more than 20+ years of experience and a proven track record of driving sustainable results and successful outcomes at biotech and pharmaceutical companies. Using an action-oriented leadership style characterized by confidence, empathy, and pragmatism, Dr. Demuth has managed teams globally across transformational and integrational activities. At Worldwide, he works cross-functionally to drive business development in Europe, collaborates with stakeholders to build Worldwide’s oncology brand in Europe, and fosters relationships with clients and KOLs.
Ask Dr. Demuth a question
Submit an RFP. Ask a Question
Throughout his distinguished career as a recognized expert in oncology, Dr. Demuth has held critical leadership roles across various organizations. As Chief Research and Development Officer at Morphosys AG, he played an integral role in pipeline prioritization and acceleration, helping to facilitate a $2.9B acquisition by Novartis based on pivotal Phase III Study results for Pelabresib in myelofibrosis. He additionally helped secure the first U.S. IND for an immuno-oncology drug while the Chief Medical Officer at Pieris Pharmaceuticals.
As the Vice President and Head of Global Clinical Development at Merck KGAA, Dr. Demuth led the global submission and approval of the targeted oncology drug, Tepmetko, marking the first approval in 15 years. In addition, he has helped establish a strong performance-oriented biosimilar development group and successfully implemented people development programs in a global organization. Dr. Demuth’s expertise in all aspects of drug development, from preclinical research to regulatory approval, is invaluable to Worldwide’s strategic, operational, scientistic, and medical approach to clinical excellence.
Based in Munich, Germany, Dr. Demuth is a member of the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO). He received his MD from Johannes Gutenberg University, with a doctoral thesis on in vitro motility of malignant glioma cells, and he completed his Post-Doctoral Fellow at the Translational Genomics Research Institute.
